Maxor National Pharmacy Services provides pharmacy management, specialty pharmacy services, and pharmacy benefit management services, self-described as transforming pharmacy care.

Maxor National Pharmacy Services

Affinity Bio Technologies specializes in the production and distribution of bio-stimulant fertilizers and agricultural products. self-described as a provider of physiological and biostimulant range.

Affinity Bio Technologies

Maxor National Pharmacy Services, LLC | 69,815 followers on LinkedIn. Maxor is a leading pharmacy care solutions company dedicated to improving patient outcomes and lowering the total cost of care through our clinically integrated set of pharmacy care services. Our teams help optimize the pharmacy experience for patients, our customers, their employees, and members whether it’s through our customized pharmacy benefit offerings; providing access to prescription medications and therapies through our home delivery and specialty pharmacies; or delivering clinical and financial value with our end-to-end pharmacy management solutions. With a legacy of exceptional service and deep clinical and pharmacy expertise, Maxor has been a trusted partner enabling pharmacy care since 1926.

Lane Pollock

Director of Business Development - helping hospitals and health centers maximize their pharmacy operations

Krista Scanlon

Larry Hofmann

CHRO, Maxor National Pharmacy Services

Joe Ellison

Maxor National Pharmacy Services, LLC

Read our latest blog about how advancements in #Diabetes treatment improve patient outcomes: https://lnkd.in/gfV6NYdy #WorldDiabetesDay #PatientCare

Have you read our latest article in the 340B Report : The Evolving Impact of 340B on Specialty Pharmacy: Opportunities and Challenges by William Riley ? Learn how the current state of the #340B program intersects with specialty pharmacy as well as the opportunities and challenges stakeholders face: https://lnkd.in/eCyrvR6f . #Protect340B #SpecialtyPharmacy

Read our latest blog about how certain #SDOH factors impact breast cancer medication adherence: https://lnkd.in/g9Z6yxrG #BreastCancer #PatientCare #Adherence

What are the top challenges driving pharmacy spend? • High-cost diabetes and obesity therapies • High-cost specialty and gene and cell therapies • Biosimilar market expansion Learn more about trends driving and solutions to mitigate pharmacy spend in Maxor’s Insights Report: https://lnkd.in/gEf_6h23 #Pharmacy #PBM #DrugTrend

We're at International Foundation of Employee Benefit Plans (IFEBP) 's Annual Conference in San Diego this week! Stop by Booth #1010 to talk with our experts.

Don't forget to visit our team of experts at Booth #413 at Becker's Healthcare CEO/CFO Forum!

Are you capturing value opportunities in your pharmacy? Our recent survey of healthcare leaders shows that more than half of respondents are missing revenue opportunities: • 52% on payer network inclusion • 54% on primary network access • 57% on contact pharmacy opportunities • 68% on limited distribution drug access Download our Pharmacy Market Report today to learn more about trends, opportunities, and how a partner, like Maxor, can help create value in your pharmacy: https://lnkd.in/gPvdM3iP #PharmacyValue #HealthSystems #Hospitals

Today, we honor all the brave men and women who have served our country. We are grateful for your courage, commitment, and sacrifices. We recognize the dedication you’ve shown and the impact you continue to make protecting our freedom and securing our safety every day. Thank you for your service! #VeteransDay #Gratitude #Honor

We’re speaking at The Health Management Academy (THMA) Chief Physician Executive Circle next week in Washington D.C.! Don’t miss Joel Wright moderating a panel on Tuesday, 11/12, Optimizing Pharmacy Strategy: Maximizing Value in Specialty and 340B Programs. See you there! #SpecialtyPharmacy #340B #PharmacyValue

We’re exhibiting at the #Becker ’s Summit in Chicago next week! Come visit us at Booth #413 to learn how Maxor helps create value in your health system pharmacy. Don’t miss Nicole Shoquist participating in a panel discussion Thursday, 11/14, “The 340B Program: What's Often Not Discussed, and How to Leverage Your System's Strategy” See you there! #HealthSystems #340B #PharmacyValue

Metric
Company Name	Maxor National Pharmacy Services	Affinity Bio Technologies
Symbol
MSH ID	COM:MAXOR	AU:COM:AFFINITYBIOTECH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Goods
Industry	Pharmaceuticals	Agriculture
Country	US	AU
Stage	Debt Financing
Employee Count
Website	maxor.com	affinitybiotech.com.au
LinkedIn	maxor-national-pharmacy-services-corp-	affinity-biotech-inc.
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	34.92K
Web Traffic Growth	0.17
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MAXO

COM:MAXOR

Maxor National Pharmacy Services

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue